[{"title":"NSF Early-concept Grants for Exploratory Research (EAGER)","agency":"National Science Foundation","logo":"assets//logos//nsf.png","dueDate":"Contact the NSF program officer(s)","fundingLevel":"up to $300K and of up to two years duration","website":"https://www.nsf.gov/pubs/policydocs/pappg19_1/pappg_2.jsp#IIE1","description":"The EAGER funding mechanism may be used to support exploratory work in its early stages on untested, but potentially transformative, research ideas or approaches. This work may be considered especially \"high risk-high payoff\" in the sense that it, for example, involves radically different approaches, applies new expertise, or engages novel disciplinary or interdisciplinary perspectives.\r\n•\tThese exploratory proposals may also be submitted directly to an NSF program, but the EAGER mechanism should not be used for projects that are appropriate for submission as regular (i.e., non-EAGER) NSF proposals.\r\n•\tPI(s) must contact the NSF program officer(s) whose expertise is most germane to the proposal topic \r\n•\tThe Project Description is expected to be brief (five to eight pages) and include clear statements as to why this project is appropriate for EAGER funding, including why it does not fit into existing programs and why it is a good fit for EAGER. \r\n•\tup to $300K and of up to two years duration. "},{"title":"Dept of Energy Seeking Input and Collaboration on Science and Technology Response to COVID-19","agency":"United States Department of Energy","logo":"assets//logos//doe.png","dueDate":"Responses will be reviewed beginning March 18, 2020. ","fundingLevel":"Unspecified","website":"https://science.osti.gov/-/media/sc-1/pdf/COVID-19-letter.pdf?la=en&hash=2A142317F56F185FC3E2CEF0AEAD6CACB3E70C7F","description":"The Department is acting rapidly to leverage, and when appropriate provide prioritized access to, the full range of DOE user facilities and other facilities available at national laboratories to support the national and international effort to address COVID-19. DOE encourages you to consider scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. Please send research questions that the scientific community may address with DOE resources by email to SC.DCL@science.doe.gov. More information can be found in the Dear Colleague Letter on DOE’s Coronavirus Resources Hub. Responses will be reviewed beginning March 18, 2020. "},{"title":"Decision, Risk and Management Sciences  (DRMS)","agency":"National Science Foundation","logo":"assets//logos//nsf.png","dueDate":"8/18/2020","fundingLevel":"Unspecified","website":"https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5423","description":"The Decision, Risk and Management Sciences program supports scientific research directed at increasing the understanding and effectiveness of decision making by individuals, groups, organizations, and society. Disciplinary and interdisciplinary research, doctoral dissertation research improvement grants (DDRIGs), and conferences are funded in the areas of judgment and decision making; decision analysis and decision aids; risk analysis, perception, and communication; societal and public policy decision making; management science and organizational design. The program also supports small grants that are time-critical (Rapid Response Research - RAPID) and small grants that are high-risk and of a potentially transformative nature (EArly-Concept Grants for Exploratory Research - EAGER). For detailed information concerning these two types of grants, please review Chapter II.E of the NSF Proposal & Award Policies & Procedures Guide (PAPPG)."},{"title":"Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)","agency":"National Science Foundation","logo":"assets//logos//nsf.png","dueDate":"Unspecified","fundingLevel":"Unspecified","website":"https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp","description":"The NSF Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program. "},{"title":"Leading Engineering for America’s Prosperity, Health, and Infrastructure (LEAP-HI) ","agency":"National Science Foundation","logo":"assets//logos//nsf.png","dueDate":"Letter of Intent due July 15, 2020; full proposal due September 15, 2020","fundingLevel":"$6,500,000 to $7,500,000 for 4-7 awards","website":"https://www.nsf.gov/pubs/2017/nsf17602/nsf17602.htm","description":"The LEAP HI program challenges the engineering research community to take a leadership role in addressing demanding, urgent, and consequential challenges for advancing America’s prosperity, health and infrastructure. LEAP HI proposals confront engineering problems that are too complex to yield to the efforts of a single investigator --- problems that require sustained and coordinated effort from interdisciplinary research teams, with goals that are not achievable through a series of smaller, short-term projects. LEAP HI projects perform fundamental research that may lead to disruptive technologies and methods, lay the foundation for new and strengthened industries, enable notable improvements in quality of life, or reimagine and revitalize the built environment."},{"title":"NSF Grants for Rapid Response Research (RAPID)","agency":"National Science Foundation","logo":"assets//logos//nsf.png","dueDate":"Unspecified","fundingLevel":"up to $200K and of one year duration. ","website":"https://www.nsf.gov/pubs/policydocs/pappg19_1/pappg_2.jsp#IIE1","description":"The RAPID funding mechanism is used for proposals having a severe urgency with regard to availability of, or access to data, facilities or specialized equipment, including quick-response research on natural or anthropogenic disasters and similar unanticipated events.  PI must contact the NSF program officer(s) whose expertise is most germane to the proposal topic Project Description is brief – two to five pages - and include clear statements as to why the proposed research is of an urgent nature and why a RAPID award would be the most appropriate mechanism for supporting the proposed work. "},{"title":"Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)","agency":"National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences (NIGMS)","logo":"assets//logos//nih.png","dueDate":"2/6/2021","fundingLevel":"Unspecified","website":"https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-030.html","description":"NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens. NIAID and NIGMS are therefore offering Competitive Revisions to active grants addressing research objectives described below."},{"title":"Multidisciplinary Studies to Improve Influenza Transmission ","agency":"National Institute of Allergy and Infectious Diseases","logo":"assets//logos//nih.png","dueDate":"6/23/2020","fundingLevel":"Recommended budgets of up to $2 million in direct costs per year may be requested. NIAID intends to commit $6 million in FY2021 to fund up to 3 awards.","website":"https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-008.html","description":"The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to comprehensively investigate the dynamics and drivers of influenza transmission between humans. This FOA will support research to: (1) improve detection and sampling of influenza viral particles from the air; (2) develop novel assays to assess viability and infectivity of influenza viral particles collected from the air; and (3) comprehensively evaluate the contribution of viral, host, physical, and environmental factors to influenza transmission between humans.  "},{"title":"2020 Emergency Grants Application","agency":"Foundation for Contemporary Arts","logo":"assets//logos//fca.png","dueDate":"12/8/2020","fundingLevel":"$500-2500","website":"https://foundationforcontemporaryarts.submittable.com/submit/148906/2020-emergency-grants-application","description":"Artist Support from Foundation for Contemporary Arts Emergency Grants is available to provide urgent funding for visual and performing artists who have sudden, unanticipated opportunities to present their work to the public when there is insufficient time to seek other sources of funding; and/or incur unexpected or unbudgeted expenses for projects close to completion with committed exhibition or performance dates. "},{"title":"COVID-19 Relief Fund Application","agency":"Foundation for Contemporary Arts","logo":"assets//logos//fca.png","dueDate":"12/8/2020","fundingLevel":1000,"website":"https://foundationforcontemporaryarts.submittable.com/submit/162848/covid-19-relief-fund-application","description":"In light of the impact of the COVID-19 pandemic on the artist community, the Foundation for Contemporary Arts is creating a temporary fund to meet the needs of experimental artists who have been impacted by the economic fallout from postponed or canceled performances and exhibitions. If you are unsure about whether your work is experimental, you can see other artists we have supported on our Instagram and our website. For as long as our Board of Directors determines it is necessary and prudent to do so, the Foundation will disburse $1,000 grants to artists who have had performances or exhibitions canceled or postponed because of the COVID-19 virus."},{"title":"Travel and Subsistence Funding to Support LMIC Engagement During the COVID-19 Outbreak","agency":"National Institute for Health Research","logo":"assets//logos//nihr.png","dueDate":"Continuous Submission","fundingLevel":"Not Specified","website":"https://www.nihr.ac.uk/documents/travel-and-subsistence-funding-to-support-lmic-engagement-during-the-covid-19-outbreak-guidance/24356","description":"The awards will provide travel and subsistence funding to appropriately qualified public health professionals, clinicians and academics who wish to offer science and technical advice to support the immediate response to COVID-19 in low and middle-income countries."},{"title":"RFP -- AMENDMENT --- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement","agency":"Department of Health & Human Services","logo":"assets//logos//dhhs.png","dueDate":"03-Feb-2023 ","fundingLevel":"Not Specified","website":"https://beta.sam.gov/opp/f922eb52cec446c5875811752bf2d34c/view","description":"Please see Special Instructions 001 Issuance for Easy Broad AgencyAnnouncement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of itsEZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. See attachment(s).This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest(AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) inthe Office of Biomedical Advanced Research and Development Authority(BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal AcquisitionRegulation (FAR). Abstract submissions selected for award are consideredto be the result of full and open competition and in full compliance with41 U.S.C. § 3301.Additional beta.sam.gov information"},{"title":"AWS Diagnostic Development Initiative (DDI)","agency":"Amazon Web Services","logo":"assets//logos//aws.png","dueDate":"30-Jun-2020 ","fundingLevel":"20,000,000 USD","website":"https://aws.amazon.com/government-education/nonprofits/disaster-response/diagnostic-dev-initiative/","description":"The AWS Diagnostic Development Initiative (DDI) provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks. Although vaccine and treatment development research is generally funded by private foundations and government agencies, fast and reliable diagnostic techniques are slow to be developed. Accurate testing and diagnosis at point-of-care or regional locations for patients with COVID-19 is critical to early intervention and treatment. "},{"title":"C19 – Work From Home Cybersecurity Grant","agency":"Campus Consortium","logo":"assets//logos//campus-consortium.png","dueDate":"03-Apr-2020 ","fundingLevel":"100,000 USD","website":"https://www.campusconsortium.org/philanthropy/grant-programs/c19-work-from-home-cybersecurity-grant/","description":"\r\nIn light of the COVID-19 pandemic, the Work From Home Cybersecurity Grant is designed to give institutions the ability to secure access to enterprise systems and applications as students, faculty and staff take online courses and work from home. "},{"title":"C19 – Artificial Intelligence for Rapid Response Grant","agency":"Campus Consortium","logo":"assets//logos//campus-consortium.png","dueDate":"03-Apr-2020 ","fundingLevel":"50,000 USD","website":"https://www.campusconsortium.org/philanthropy/grant-programs/c19-artificial-intelligence-for-rapid-response-grant/","description":"Due to the recent C19 pandemic, the Campus Consortium has partnered with Unifyed to provide the technology platform and services for the Artificial Intelligence for Rapid Response Grant. The Artificial Intelligence for Rapid Response Grant is designed to help schools address the high call and query volume they are receiving by providing Unifyed’s Yoda Rapid Response, an AI-enabled chat service that can help answer FAQ and provide self-help assistance to students, faculty and staff. "},{"title":"Building Capacity for National Public Health Institutes","agency":"Center for Global Health/CDC/DHHS","logo":"assets//logos//cdc.png","dueDate":"04-May-2020 ","fundingLevel":"15,000,000 USD","website":"https://www.grants.gov/web/grants/view-opportunity.html?oppId=323073","description":"\r\n\r\nConsolidating and organizing public health expertise and systems within a National Public Health Institute (NPHI) is a successful way for countries to carry out essential public health functions and improve their accountability and efficiency. The CDC, with over 70 years of experience as the U.S. NPHI, is helping countries around the world increase surveillance, laboratory, and outbreak response capacity to improve recognition of and response to health threats. An NPHI coupled with stronger local outbreak detection and response capabilities offers a sustainable solution for building global public health capacity, achieving global health security, and increasing public health impact. "},{"title":"RFP --Prototype Development to Combat Novel Coronavirus Disease COVID-19","agency":"Department of the Army","logo":"assets//logos//dod.png","dueDate":"15-Apr-2020 ","fundingLevel":"Not Specified","website":"https://beta.sam.gov/opp/53badf9fb02349e78839a541495efc6a/view ","description":"The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19). "},{"title":"MRFF – 2020 Respiratory Medicine Clinical Trials Research on COVID-19 Grant Opportunity (Defunct)","agency":"National Health and Medical Research Council","logo":"assets//logos//nhmrc.png","dueDate":"06-Apr-2020 ","fundingLevel":"Not Specified","website":"https://www.grants.gov.au/?event=public.GO.show&GOUUID=341E3C7A-9516-311D-915D5D11DFB9AAB4","description":"\t\r\n\r\nThe Australian Government has committed $2.4 billion to a Coronavirus (COVID-19) National Health Plan to support our health system to manage the outbreak of novel coronavirus in Australia. The package provides support across primary care, aged care, hospitals and research, and includes $30 million over two years from the MRFF for a Coronavirus Research Response comprising vaccine, anti-viral and respiratory medicine research. These research priorities are in line with the priorities agreed at the recent Coronavirus Research Roundtable. "},{"title":"Hospital Associations COVID-19 Preparedness and Response Activities","agency":"Assistant Secretary for Preparedness and Response/DHHS","logo":"assets//logos//dhhs.png","dueDate":"30-Mar-2020 ","fundingLevel":"Not Specified","website":"https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=66890","description":"The purpose of this NOFO is to support the urgent preparedness and response needs of hospitals, health systems, and physicians and nurses on the front lines of the COVID-19 outbreak in order to help prepare them to identify, isolate, assess, transport, and treat patients with or persons under investigation for COVID-19 or other special pathogens. Funding will be distributed to hospital associations using a formula specific to COVID-19, which takes into account criteria such as at-risk populations and other vulnerabilities associated with this pandemic (e.g., population density; size of populations with increased risk for mortality from COVID-19, such as older adults and individuals with comorbid health conditions; and health care capacity)."},{"title":"Innovative Medicines Initiative 2 (IMI2) Joint Undertaking – 21st Call -- Development of Therapeutics and Diagnostics Combatting Coronavirus Infections","agency":"European Commission","logo":"assets//logos//eu.png","dueDate":"31-Mar-2020 ","fundingLevel":"49,500,000 USD","website":"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/call-fiche_h2020-jti-imi2-2020-21-single-stage_en.pdf","description":"Proposals submitted under this topic are expected to advance our knowledge of SARS-CoV-2 specifically and the wider coronavirus family in general with the aim of contributing to an efficient patient management and/or public health preparedness and response to current and future outbreaks of coronavirus infection. "},{"title":"Call For Proposals","agency":"Innovative Medicines Initiative (IMI)","logo":"assets//logos//imi.png","dueDate":"31-Mar-2020 ","fundingLevel":"Not Specified","website":"https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-20","description":"The Innovative Medicines Initiative (IMI) has launched its 20th and 21st calls for proposals. \r\n\r\nTopics for Call 20 include the following:\r\n\r\n    Topic 1: Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis;\r\n    Topic 2: Innovations to accelerate vaccine development and manufacture;\r\n    Topic 3: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB). This topic is part of the IMI AMR Accelerator Programme. Applicants should also read the Questions and Answers on the programme (document last updated November 2019);\r\n    Topic 4: Tumour plasticity;\r\n    Topic 5: Proton versus photon therapy for oesophageal cancer – a trimodality strategy;\r\n    Topic 6: Handling of protein drug products and stability concerns."},{"title":"RFP -- AMENDMENT--Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)","agency":"Department of Health & Human Services","logo":"assets//logos//dhhs.png","dueDate":"31-Oct-2020 ","fundingLevel":"Not Specified","website":"https://beta.sam.gov/opp/cf2836e2f4b3406f9f492230ece030c7/view","description":"The latest BARDA BAA is amendment 12 posted on February 10, 2020 which incorporates changes to AOI 7-Diagnostics. BARDA is now accepting submissions to AOI 7.7 for development of assays for coronaviruses. Due to an overwhelming response to Area of Interest 7, BARDA is temporarily closing AOI's; Innovations (7.1), biothreats (7.2), antibiotic resistance (7.3) and influenza (7.6). AOI's radiation exposure/biodosimetry (7.4), and chemical threat exposure (7.5) remain closed. The final whte paper\r\nsubmission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter."},{"title":"Coronavirus (COVID-19) Therapeutics Development and Testing for Rapid Deployment","agency":"LifeArc","logo":"assets//logos//lifearc.png","dueDate":"06-Apr-2020 ","fundingLevel":"Not Specified","website":"https://www.lifearc.org/funding/covid-19/","description":"LifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication. "},{"title":"COVID-19 Rapid Response","agency":"Science Foundation Ireland","logo":"assets//logos//sfi.png","dueDate":"Continuous Submission","fundingLevel":"Not Specified","website":"http://www.sfi.ie/funding/funding-calls/covid19-rapid-response/SFI-EI-IDA-COVID-19-Rapid-Response-Call.pdf","description":"The SFI, Enterprise Ireland, IDA Ireland rapid response call is an agile and adaptive initiative to support development of innovative solutions (including STEM-based, social/behavioural science) that can have rapid demonstrable impact on the current COVID-19 crisis in Ireland. "},{"title":"Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nations Health","agency":"Centers for Disease Control and Prevention/DHHS","logo":"assets//logos//cdc.png","dueDate":"02-Apr-2020 ","fundingLevel":"Not Specified","website":"https://www.grants.gov/web/grants/view-opportunity.html?oppId=324734","description":"The purpose of this notice of funding opportunity (NOFO) is to announce the availability of emergency supplemental funding for the organizations that were previously awarded funding under Funding Strategy 1 of CDC-RFA-OT18-1802: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health."},{"title":"Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) – CoV Pandemic Response","agency":"Medical CBRN Defense Consortium (MCDC)","logo":"assets//logos//mcdc.png","dueDate":"31-May-2020 ","fundingLevel":"Not Specified","website":"https://www.medcbrn.org/cov-pandemic-response/","description":"The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.).  "},{"title":"Epidemic Preparedness: COVID-19 Funding Call","agency":"Wellcome Trust","logo":"assets//logos//wellcometrust.png","dueDate":"Continuous Submission","fundingLevel":"Not Specified","website":"https://wellcome.ac.uk/funding/schemes/epidemic-preparedness-covid-19","description":"\r\nThis call aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and to increase research and response capacity. It's part of an existing partnership between Wellcome and the UK Department for International Development (DFID) through the Joint Initiative on Research in Epidemic Preparedness and Response to help low- and middle-income countries prepare for and tackle epidemics. "},{"title":"AHA COVID-19 Coordinating Center","agency":"American Heart Association","logo":"assets//logos//aha.png","dueDate":"06-Apr-2020 ","fundingLevel":"150,000 USD","website":"https://professional.heart.org/professional/ResearchPrograms/UCM_505867_AHA-Rapid-Response-Grant-COVID-19-and-its-Cardiovascular-Impact.jsp","description":"There is an urgent need to better understand the pathobiology and the clinical implications of the viral infection that leads to the morbidity and mortality seen with COVID-19. To address this need, the American Heart Association (AHA) invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19. To ensure rapid dissemination of results to the medical and research communities, one grant recipient will be selected to establish the COVID-19 Coordinating Center. This center will coordinate communication among the awardees, help establish collaborations where appropriate, receive results from all awardees and serve to coordinate dissemination of all findings resulting from this mechanism. "},{"title":"AHA Rapid Response Grant -- COVID-19 and Its Cardiovascular Impact","agency":"American Heart Association","logo":"assets//logos//aha.png","dueDate":"06-Apr-2020 ","fundingLevel":"100,000 USD","website":"https://professional.heart.org/professional/ResearchPrograms/UCM_505867_AHA-Rapid-Response-Grant-COVID-19-and-its-Cardiovascular-Impact.jsp","description":"\t\r\nThere is an urgent need to better understand the pathobiology and the clinical implications of the viral infection that leads to the morbidity and mortality seen with COVID-19. To address this need, the American Heart Association (AHA) invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis."},{"title":"Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)","agency":"National Institute of Allergy and Infectious Diseases/NIH/DHHS","logo":"assets//logos//nih.png","dueDate":"09-Sep-2020 ","fundingLevel":"275,000 USD","website":"https://grants.nih.gov/grants/guide/pa-files/PAR-18-781.html","description":"National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals."},{"title":"Enhancing Global Health Security: Expanding Efforts and Strategies to Protect and Improve Public Health Globally","agency":"Center for Global Health/CDC/DHHS","logo":"assets//logos//cdc.png","dueDate":"27-Apr-2020 ","fundingLevel":"75,000,000 USD","website":"https://www.grants.gov/web/grants/view-opportunity.html?oppId=320394","description":"\r\n\r\nThis Notice of Funding Opportunity (NOFO) seeks to build upon activities funded by CDC to support Global Health Security (GHS) through implementation of programs and activities that focus on protecting and improving health globally through partnerships with Ministries of Health and other governmental institutions. After five years of implementing and strengthening global health security systems, the U.S. Government (USG) will continue to advance prevent, detect, and respond strategies to mitigate threats. "},{"title":"Global Health Security Partnerships: Expanding and Improving Public Health Laboratory Strategies and Systems.","agency":"Center for Global Health/CDC/DHHS","logo":"assets//logos//cdc.png","dueDate":"04-May-2020 ","fundingLevel":"25,000,000 USD","website":"https://www.grants.gov/web/grants/view-opportunity.html?oppId=320733","description":"Activities under this Notice of Funding Opportunity (NOFO) should focus on protecting and improving public health globally by: 1) strengthening public health laboratory systems; 2) improving public health laboratory workforce; 3) improving biorisk management; 4) reinforcing emergency laboratory preparedness; and 5) enhancing laboratory quality management systems. Additionally, laboratory recipients previously funded under CDC-RFA-GH15-1632 may apply to expand efforts in additional countries with special consideration given to those countries within the regions listed in the funding strategy section of this NOFO. Recipients should be able to modify their activities based on agency prioritization."},{"title":"Global Health Security Partner Enhancement : Expanding Efforts to Improve Surveillance and Laboratory Data Interoperability","agency":"Center for Global Health/CDC/DHHS","logo":"assets//logos//cdc.png","dueDate":"04-May-2020 ","fundingLevel":"5,000,000 USD","website":"https://www.grants.gov/web/grants/view-opportunity.html?oppId=322255","description":"\t\r\n\r\nThe U.S. government's (USG) Global Health Security Agenda (GHSA) envisions a world safe and secure from global health threats posed by infectious diseases, and the current Ebola epidemic in West Africa further underscores the economic and humanitarian impacts of infectious diseases. "},{"title":"Strengthening Global Field Epidemiology Training Program (FETP) Network","agency":"Center for Global Health/CDC/DHHS","logo":"assets//logos//cdc.png","dueDate":"27-Apr-2020 ","fundingLevel":"105,000,000 USD","website":"https://www.grants.gov/web/grants/view-opportunity.html?oppId=322659","description":"Development of a well-trained epidemiologic public health workforce in surveillance, outbreak detection and response is essential in meeting Global Health Security objectives. In partnership with Ministries of Health and other public and private stakeholders, CDC seeks to accelerate progress toward a world safe and secure from infectious disease threats by building workforce capacity through creation and support of a global network of field epidemiology and training program (FETP). "}]